Cargando…
Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection
BACKGROUND & AIMS: There is insufficient data on the clinical course of chronic hepatitis B (CHB) patients in the immune-tolerant (IT) and immune-clearance, inactive (IC) phases over a long follow-up period. DESIGN: We enrolled 466 CHB patients from our historical cohort, including 56 IT+MA (mi...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714106/ https://www.ncbi.nlm.nih.gov/pubmed/34962955 http://dx.doi.org/10.1371/journal.pone.0261878 |
_version_ | 1784623848498397184 |
---|---|
author | Suzuki, Takanori Matsuura, Kentaro Nagura, Yoshihito Iio, Etsuko Ogawa, Shintaro Fujiwara, Kei Nojiri, Shunsuke Kataoka, Hiromi Tanaka, Yasuhito |
author_facet | Suzuki, Takanori Matsuura, Kentaro Nagura, Yoshihito Iio, Etsuko Ogawa, Shintaro Fujiwara, Kei Nojiri, Shunsuke Kataoka, Hiromi Tanaka, Yasuhito |
author_sort | Suzuki, Takanori |
collection | PubMed |
description | BACKGROUND & AIMS: There is insufficient data on the clinical course of chronic hepatitis B (CHB) patients in the immune-tolerant (IT) and immune-clearance, inactive (IC) phases over a long follow-up period. DESIGN: We enrolled 466 CHB patients from our historical cohort, including 56 IT+MA (mildly active), 134 IC, 230 with chronic active hepatitis (CH) and 46 with liver cirrhosis (LC), who were categorized to each phase by at least one year of follow-up period from the first visit to our hospital. We investigated long-term risks, and their factors, of developing hepatocellular carcinoma (HCC), and the transition between the clinical phases, especially in the IT+MA and IC groups. RESULTS: Of the 56 patients in the IT+MA group, 27 remained the IT+MA phase, but 29 transitioned to the CH phase and started nucleot(s)ide analogue (NA) treatment during the follow-up period. Meanwhile, of the 134 patients in the IC group, only 5 started NA treatment after progressing to the CH phase. The development of HCC from the IT+MA, IC, CH, and LC groups was observed in 2, 2, 9, and 20 cases, respectively. The cumulative incidence rates of developing HCC in the IT+MA, IC, CH, and LC groups were 9.9, 1.8, 3.0, and 53.1% at 10 years. In the CH and LC group, patients who developed HCC were older, had higher levels of FIB-4 index, M2BPGi, HBcrAg and AFP, and had lower levels of albumin and platelet counts. In CH patients, FIB-4 index levels were elevated at the diagnosis of HCC compared to baseline, whereas these decreased during the follow-up period in non-HCC patients. CONCLUSIONS: HCC occurred at a certain rate among patients in the IT+MA and IC groups. Careful follow-up is required for CH patients with higher levels of FIB-4 index and/or M2BPGi because of the high incidence of HCC development. (299 words) |
format | Online Article Text |
id | pubmed-8714106 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-87141062021-12-29 Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection Suzuki, Takanori Matsuura, Kentaro Nagura, Yoshihito Iio, Etsuko Ogawa, Shintaro Fujiwara, Kei Nojiri, Shunsuke Kataoka, Hiromi Tanaka, Yasuhito PLoS One Research Article BACKGROUND & AIMS: There is insufficient data on the clinical course of chronic hepatitis B (CHB) patients in the immune-tolerant (IT) and immune-clearance, inactive (IC) phases over a long follow-up period. DESIGN: We enrolled 466 CHB patients from our historical cohort, including 56 IT+MA (mildly active), 134 IC, 230 with chronic active hepatitis (CH) and 46 with liver cirrhosis (LC), who were categorized to each phase by at least one year of follow-up period from the first visit to our hospital. We investigated long-term risks, and their factors, of developing hepatocellular carcinoma (HCC), and the transition between the clinical phases, especially in the IT+MA and IC groups. RESULTS: Of the 56 patients in the IT+MA group, 27 remained the IT+MA phase, but 29 transitioned to the CH phase and started nucleot(s)ide analogue (NA) treatment during the follow-up period. Meanwhile, of the 134 patients in the IC group, only 5 started NA treatment after progressing to the CH phase. The development of HCC from the IT+MA, IC, CH, and LC groups was observed in 2, 2, 9, and 20 cases, respectively. The cumulative incidence rates of developing HCC in the IT+MA, IC, CH, and LC groups were 9.9, 1.8, 3.0, and 53.1% at 10 years. In the CH and LC group, patients who developed HCC were older, had higher levels of FIB-4 index, M2BPGi, HBcrAg and AFP, and had lower levels of albumin and platelet counts. In CH patients, FIB-4 index levels were elevated at the diagnosis of HCC compared to baseline, whereas these decreased during the follow-up period in non-HCC patients. CONCLUSIONS: HCC occurred at a certain rate among patients in the IT+MA and IC groups. Careful follow-up is required for CH patients with higher levels of FIB-4 index and/or M2BPGi because of the high incidence of HCC development. (299 words) Public Library of Science 2021-12-28 /pmc/articles/PMC8714106/ /pubmed/34962955 http://dx.doi.org/10.1371/journal.pone.0261878 Text en © 2021 Suzuki et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Suzuki, Takanori Matsuura, Kentaro Nagura, Yoshihito Iio, Etsuko Ogawa, Shintaro Fujiwara, Kei Nojiri, Shunsuke Kataoka, Hiromi Tanaka, Yasuhito Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection |
title | Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection |
title_full | Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection |
title_fullStr | Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection |
title_full_unstemmed | Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection |
title_short | Development of hepatocellular carcinoma from various phases of chronic hepatitis B virus infection |
title_sort | development of hepatocellular carcinoma from various phases of chronic hepatitis b virus infection |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8714106/ https://www.ncbi.nlm.nih.gov/pubmed/34962955 http://dx.doi.org/10.1371/journal.pone.0261878 |
work_keys_str_mv | AT suzukitakanori developmentofhepatocellularcarcinomafromvariousphasesofchronichepatitisbvirusinfection AT matsuurakentaro developmentofhepatocellularcarcinomafromvariousphasesofchronichepatitisbvirusinfection AT nagurayoshihito developmentofhepatocellularcarcinomafromvariousphasesofchronichepatitisbvirusinfection AT iioetsuko developmentofhepatocellularcarcinomafromvariousphasesofchronichepatitisbvirusinfection AT ogawashintaro developmentofhepatocellularcarcinomafromvariousphasesofchronichepatitisbvirusinfection AT fujiwarakei developmentofhepatocellularcarcinomafromvariousphasesofchronichepatitisbvirusinfection AT nojirishunsuke developmentofhepatocellularcarcinomafromvariousphasesofchronichepatitisbvirusinfection AT kataokahiromi developmentofhepatocellularcarcinomafromvariousphasesofchronichepatitisbvirusinfection AT tanakayasuhito developmentofhepatocellularcarcinomafromvariousphasesofchronichepatitisbvirusinfection |